Theravance Biopharma Completes Enrollment In Pivotal Phase 3 Trial For Blood Pressure Disorder, Advances Phase 3 CYPRESS Study Targeting Rare Neurodegenerative Disease Affecting MSA Patients

Author: Benzinga Newsdesk | August 25, 2025 05:05am

Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ:TBPH), today announced completion of enrollment in the open-label portion of its pivotal Phase 3 CYPRESS study in patients with symptomatic neurogenic orthostatic hypotension (nOH) due to multiple system atrophy (MSA), a rare and progressive neurodegenerative disorder. nOH is a devastating condition affecting approximately 80% of MSA patients and is characterized by sudden drops in blood pressure upon standing, leading to symptoms such as dizziness, fainting, and blurry vision. These symptoms can lead to serious consequences, including falls, disability, and loss of independence. Despite its severity and impact, there is a lack of effective and durable treatment options that are specifically designed to treat nOH in patients with MSA.

Posted In: TBPH